AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01354301
Drug: Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
Trial: NCT01354301
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
Trial: NCT01354301
Drug: Basiliximabe
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: days 0 and 4, according to the package insert instructions.
Trial: NCT01354301
Drug: mycophenolate sodium
RxNorm normalized name: Mycophenolate Sodium
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 720 mg BID. This dose will be reduced according to adverse events.
Trial: NCT01354301
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
Trial: NCT01354301
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
Trial: NCT01354301
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
Trial: NCT01311570
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.~From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician.
Trial: NCT02718378
Drug: estetrol
RxNorm normalized name: estetrol
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01082315
Drug: Erbitux (Cetuximab)
RxNorm normalized name: Erbitux
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. Cetuximab 2mg/ml will be administered intravenously via in-line filtration with an infusion pump, gravity drip or a syringe pump. For the initial dose, the recommended infusion period is 120 minutes and for the subsequent weekly doses, the recommended infusion period is 60 minutes.
Trial: NCT04202484
Drug: Toripalimab combined with oxaliplatin and Tegafur,Gimeracil and Oteracil Porassium Capsules
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Toripalimab: 240mg IV Q3W;Tegafur,Gimeracil and Oteracil Porassium Capsules: 40mg/m2 Bid PO×14d Q3W;Oxaliplatin: 130mg/m2 IV Q3W
Trial: NCT01223027
Drug: Dovitinib
RxNorm normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
Trial: NCT01223027
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
Trial: NCT02678780
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02159820
Drug: Decitabine (DTC Arm)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
Trial: NCT02159820
Drug: Paclitaxel and Carboplatin (TC Arm)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve \[AUC\] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
Trial: NCT02490800
Drug: Lisavanbulin Phase 1 dose escalation portion
RxNorm normalized name: peanut allergenic extract
DrugBank: Lisavanbulin (DB15224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 35 mg/day
Trial: NCT02490800
Drug: Lisavanbulin Phase 2a expansion portion
RxNorm normalized name: Lisavanbulin
DrugBank: Lisavanbulin (DB15224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Trial: NCT03874247
Drug: pelubiprofen 45mg
RxNorm normalized name: Flurbiprofen
DrugBank: Pelubiprofen (DB12150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bid for 3 days after meal
Trial: NCT03874247
Drug: pelubiprofen placebo
DrugBank: Pelubiprofen (DB12150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bid for 3 days after meal
Trial: NCT04134468
Drug: Pegvorhyaluronidase alfa
RxNorm normalized name: Pegvorhyaluronidase alfa
DrugBank: Pegvorhyaluronidase alfa (DB14912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04134468
Drug: Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04134468
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT01896531
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
Trial: NCT01896531
Drug: Ipatasertib
RxNorm normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ipatasertib, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
Trial: NCT01896531
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles
Trial: NCT01763554
Drug: Lu-177 DOTA-TATE
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.
Trial: NCT03927495
Drug: KN046
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cisplatin+paclitaxel will be administered once every three weeks for four cycles. During the period of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
Trial: NCT03927495
Drug: KN046
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cisplatin+paclitaxel will be administered once every three weeks for four cycles. After completion of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
Trial: NCT02324335
Drug: Brilacidin
RxNorm normalized name: Brilacidin
DrugBank: Brilacidin (DB12997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Rinse used 3 times daily for 7 weeks
Trial: NCT03388008
Drug: Belatacept
RxNorm normalized name: Belatacept
DrugBank: Belatacept (DB06681)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belatacept will be dosed at 10 mg/kg of actual body weight on days 0, 7, 14, 28, 56, and 84 then at 5 mg/kg on day 112 and every 28 days through day 364 (i.e., on days 140, 168, 196, 224, 252, 280, 308, 336, and 364)
Trial: NCT03388008
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus will be dosed enterally or sublingually within 48 hours of transplantation and the dose will be adjusted to target a trough blood level of 8-15 ng/ml
Trial: NCT03388008
Drug: ATG
RxNorm normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-thymocyte globulin will be dosed intravenously at 3 mg/kg divided into 3 daily doses starting on day 0 after transplantation
Trial: NCT03388008
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil will be dosed at 1000 mg twice daily (or if the enteric coated formulation is used, this will be dosed at 720 mg twice daily. In the standard of care arm, mycophenolate mofetil will be initiated on day 0 after transplantation, whereas in the belatacept-based immunosuppression arm, mycophenolate mofetil will be initiated on day 90 after transplantation
Trial: NCT03388008
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 500 mg will be given intravenously before perfusion of the allograft during the transplant procedure, then methylprednisolone 0.5 mg/kg will be given intravenously twice daily for 6 total doses
Trial: NCT03388008
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be dosed at 0.5 mg/kg orally daily through day 14, then 0.2 mg/kg orally daily through day 30, then 0.1 mg/kg daily through day 180, then 5 mg daily through day 365
Trial: NCT03944057
Drug: ATG-010
RxNorm normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle).~Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)
Trial: NCT03426540
Drug: Conbercept
RxNorm normalized name: Conbercept
DrugBank: Conbercept (DB12460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.
Trial: NCT01513044
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
Trial: NCT01513044
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg capsules of Roche Laboratories Inc.
Trial: NCT00466479
Drug: brimonidine
RxNorm normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02190318
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03900884
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At commencement of study: Venetoclax will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 100 and 800 mg/day depending on dose escalation results and recommendation of the safety committee.
Trial: NCT03900884
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At commencement of study: Palbociclib will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 75 and 125 mg/day depending on dose escalation results and recommendation of the safety committee.
Trial: NCT03900884
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
Trial: NCT01294293
Drug: TLR8 Agonist VTX-2337
RxNorm normalized name: VTX-801
DrugBank: VTX-801 (DB17646)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT01294293
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01885000
Drug: Brimonidine tartrate was applied cutaneously once daily for 8 days.
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01885000
Drug: Brimonidine tartrate vehicle was applied cutaneously once daily for 8 days.
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03169426
Drug: Beta Blockers Carvedilol Phosphate
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects are going to take Beta Blockers Carvedilol Phosphate (12.5mg once) before undergoing remote ischemic conditioning.
Trial: NCT00250315
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04403971
Drug: 0.12% Chlorhexidine Oral Liquid Product
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention group 1 received 10ml 0.12% chlorhexidine solution for oral rinse twice a day.
Trial: NCT02251509
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02251509
Drug: Metoprolol tartrate
RxNorm normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03908307
Drug: OZURDEX
RxNorm normalized name: Ozurdex
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Implant 700 μg
Trial: NCT03853096
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin 100mg/mL, 3mL in three locations will be administered around a surgical incision on the anterior shoulder in a standard deltopectoral approach interval. This will be a one time administration. Administration and route will be subcutaneous.
Trial: NCT03017352
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00855920
Drug: Rilonacept
RxNorm normalized name: Rilonacept
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
Trial: NCT00573534
Drug: Vyvanse
RxNorm normalized name: Vyvanse
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
Trial: NCT02781493
Drug: 2 mg Prucalopride plus 2 L Polyethylene Glycol regimen
RxNorm normalized name: polyethylene glycol 300 2 MG/ML
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
Trial: NCT02781493
Drug: 2 mg Placebo plus 2 L Polyethylene Glycol regimen
RxNorm normalized name: polyethylene glycol 300 2 MG/ML
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
Trial: NCT01466374
Drug: BMS-936557 (Anti-IP-10 Antibody)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
Trial: NCT01466374
Drug: BMS-936557 (Anti-IP-10 Antibody)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution for IV administration, Intravenous, 20 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
Trial: NCT01466374
Drug: BMS-936557 (Anti-IP-10 Antibody)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution for IV administration, Intravenous, 7.5 mg/kg, Every other week, Up to 337 days
Trial: NCT01466374
Drug: BMS-936557 (Anti-IP-10 Antibody)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution for IV administration, Intravenous, 15 mg/kg, Every other week, Up to 337 days
Trial: NCT01466374
Drug: BMS-936557 (Anti-IP-10 Antibody)
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution for IV administration, Intravenous, 15 mg/kg or optimal dose, Every other week, Open
Trial: NCT00327691
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03797001
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg subcutaneous injection, daily for 24 weeks
Trial: NCT02172469
Drug: Tiotropium inhalation powder capsule
RxNorm normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00001723
Drug: Orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
Trial: NCT01622790
Drug: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
Trial: NCT01622790
Drug: Dolutegravir 50 mg
RxNorm normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
Trial: NCT01622790
Drug: abacavir 600 mg/lamivudine 300 mg
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
Trial: NCT00086320
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02172469
Drug: Ipratropium Bromide Metered Dose Inhaler
RxNorm normalized name: ipratropium bromide Metered Dose Inhaler
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02071368
Drug: Canagliflozin, 300 mg
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
Trial: NCT02071368
Drug: Metformin XR, 500 mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
Trial: NCT02697032
Drug: Bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg
Trial: NCT03335085
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00325312
Drug: carbon dioxide, subcutaneous application
DrugBank: Carbon dioxide (DB09157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02178124
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02760355
Drug: Ledipasvir 90 mg/Sofosbuvir 400 mg
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration on one fixed dose combination tablet for 12 weeks